Enzymatic control of phenylalanine intake in phenylketonuria.

The plant enzyme phenylalanine ammonia lyase (PAL) will survive in the gut for long enough to deplete the phenylalanine derived from food protein and so reduce the rise in blood phenylalanine that otherwise occurs after a protein meal. This effect has been demonstrated in healthy adults and phenylketonuric (PKU) patients. When the enzyme was given to an untreated PKU patient for 12 consecutive days (three doses a day after food) his blood phenylalanine levels were reduced on average by a quarter. This enzyme preparation may have a place in the treatment of PKU.

Amino acid degrading enzymes for cancer therapy.

The development of microbial enzymes for cancer therapy presents difficulties not commonly experienced with biological drugs. The development of the enzyme asparaginase from Escherichia coli in the USA and of the serologically different asparaginase from the plant pathogen Erwinia carotovora in this Establishment, has not only added to the choice of antileukaemia drugs but also provided a valuable guide to the selection and development of new therapeutic enzymes. Our own programme has led to the study of enzymes that degrade other amino acids (glutamine, arginine, phenylalanine and tyrosine) that appear to be important to certain leukaemia cells. Microbes with only remote associations with man were considered as a source of these to minimize initial immunological sensitivity. In the case of erwinia asparaginase the benefits of this have probably included a lower incidence of anaphylaxis compared with the escherichia enzyme. The selection of a stable, high-affinity enzyme that operates efficiently under physiological conditions ensures effective depletion of a circulating amino acid but the choice is very limited. It is also difficult to assess from laboratory tests the likely persistence, toxicity and efficacy of the enzyme in clinical use and to arrive at meaningful biological tests for the quality control of the finished product. Some of the difficulties will be described and proposals made for criteria of acceptance for this type of drug in experimental use.

Bacterial glutaminase in treatment of acute leukaemia.

A glutaminase-asparaginase enzyme from Achromobacter sp has antitumour activity in vitro and in animals. Glutaminase was administered in doses of 3500-20 000 IU/m2 body surface area/day to six patients with acute lymphoblastic leukaemia (ALL) and three patients with acute myeloid leukaemia (AML). The enzyme had a blood half life of 80 minutes but depletion of blood glutamine persisted for 12 hours after single doses. Seven patients, including four (two with AML and two with ALL) resistant to asparaginase, received repeated doses of glutaminase. Antileukaemic effects were observed in all seven; one elderly patient developed metabolic acidosis. Study of this new antileukaemic agent in patients with acute leukaemia at an earlier stage of their disease is now justified.

The preparation of ribosomal ribonucleic acid from whole bacteria.

1. A simple method for the preparation of ribonuclease-free ribosomal RNA is described in which ribonuclease-deficient bacteria are treated with acetone and the RNA is extracted with phenol and purified by precipitating it with potassium acetate. The treatment with acetone appears to render the cell wall permeable to RNA but not to DNA during the extraction with phenol. The method thus avoids the need to disrupt the bacteria and greatly simplifies the subsequent purification. 2. The method has been used successfully with ribonuclease-deficient strains of Escherichia coli, Pseudomonas fluorescens and Staphylococcus epidermidis. The recovered purified RNA accounts for about 70% of the total ribosomal RNA and shows the normal sedimentation pattern of the 16s and 23s components in the analytical centrifuge.

Magnesium ion-independent ribonucleic acid depolymerases in bacteria.

The distribution of ribonucleases among bacteria has been determined from the examination of a wide variety of species. Bacteria that had been growing rapidly on a solid medium were harvested, treated with acetone and incubated in the presence of EDTA between pH4 and pH9. The ribonuclease activity was determined from the rate at which acid-soluble nucleotides were released. Out of nearly 200 strains examined, about 30 did not contain a detectable ribonuclease. The pH optima of ribonucleases in the remainder were sufficiently distinctive to suggest a use in taxonomy. Escherichia coli B was examined in more detail to determine the factors responsible for variations in the ribonuclease content of this bacterium. Growth rate had little influence on ribonuclease content when a complex medium containing no readily assimilable carbohydrate was used; the addition of glucose resulted in a marked increase in ribonuclease and a dependence of enzyme content on growth rate. An increase in the concentration of sodium chloride in the medium decreased the ribonuclease content of bacteria growing on it.